Plato Investment Management Ltd Acquires 1,116 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Plato Investment Management Ltd grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 41.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,777 shares of the biopharmaceutical company’s stock after buying an additional 1,116 shares during the period. Plato Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,421,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Pinney & Scofield Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the last quarter. Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Finally, Saudi Central Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $27,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, June 30th. Raymond James Financial raised Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Finally, UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Trading Down 0.1%

NASDAQ:REGN opened at $555.83 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,170.58. The company has a market cap of $58.91 billion, a PE ratio of 14.01, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a 50 day simple moving average of $563.85 and a two-hundred day simple moving average of $581.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 EPS. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.